Evidence map›Paper›PMID 33947977›Full record

ArticleCell research2021

Ultrasensitive antigen density discrimination by synNotch.

Divanshu Shukla, James L Riley

Abstract readComment
In one paragraph

Article in Cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Divanshu ShuklaDepartment of Microbiology, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, 19104, USA.
James L RileyDepartment of Microbiology, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, 19104, USA. rileyj@upenn.edu.ORCID http://orcid.org/0000-0002-1057-576X

Funding

First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Modeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2M
Microphysiological systems for modeling autoimmunity in type 1 diabetesUH3DK122644 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GADUE, PAUL J, HUH, DONGEUN · 2021 to 2023
$3.4M
Microphysiological systems for modeling autoimmunity in type 1 diabetesUG3DK122644 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GADUE, PAUL J, HUH, DONGEUN · 2019 to 2020
$2.3M
NIAID NIH HHS U19 AI149680NIAID NIH HHS UM1 AI126620NIDDK NIH HHS UG3 DK122644NIDDK NIH HHS UH3 DK122644U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI149680
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunotherapy, AdoptiveXenograft Model Antitumor Assays

Identifiers

PMID33947977
PMCPMC8249475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.